人乳寡糖2’-FL和3-FL的生物制备研究进展
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家重点研发计划 (No. 2018YFA0902200),江苏省六大人才高峰 (No. NY-056) 资助。


Recent advances in the bio-production of human milk oligosaccharides 2’-FL and 3-FL
Author:
Affiliation:

Fund Project:

National Key Research and Development Program of China (No. 2018YFA0902200), Six Talent Peaks Project in Jiangsu Province, China (No. NY-056).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    人乳寡糖 (Human milk oligosaccharides,HMO) 是母乳中重要的免疫活性成分,对婴幼儿健康起到显著促进作用。2’-岩藻糖基乳糖 (2’-FL) 是HMO的主要组分,极具应用价值,3-岩藻糖基乳糖 (3-FL) 与2’-FL的合成途径相似,两者的研究具有相互借鉴意义,近年来针对它们的研究取得了较多进展。以微生物细胞工厂为核心理念的新型生物合成途径有望将2’-FL和3-FL产业化,未来将对乳制品行业产生重要的影响。文中综述了生物技术制备2’-FL和3-FL的最新研究进展,并对未来发展趋势进行了展望。

    Abstract:

    Human milk oligosaccharides (HMO) are important immunoactive components found in breast milk. Scientific research proves that HMOs are significantly beneficial for infant health. 2’-fucosyllactose (2’-FL) is the major component of HMO, which obtained growing attentions from food industry. Besides, 3-fucosyllactose (3-FL) is another important fucosyllactose and it has a similar synthetic route comparing to 2’-FL. Thus, research of the two HMO components has interactive effects for each other. Recently, numerous publications are available for 2’-FL and 3-FL. The microbial cell factory is able to massively produce fucosyllactose via an efficient way, which will show considerable influences in dairy industry. In this paper, we review recent studies on 2’-FL and 3-FL, and discuss their prospects according to published literature and patents.

    参考文献
    相似文献
    引证文献
引用本文

徐铮,李娜,陈盈利,张雯瑞,朱婉莹. 人乳寡糖2’-FL和3-FL的生物制备研究进展[J]. 生物工程学报, 2020, 36(12): 2767-2778

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-04-12
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-12-26
  • 出版日期:
您是第位访问者
生物工程学报 ® 2024 版权所有

通信地址:中国科学院微生物研究所    邮编:100101

电话:010-64807509   E-mail:cjb@im.ac.cn

技术支持:北京勤云科技发展有限公司